|
FR2697752B1
(fr)
|
1992-11-10 |
1995-04-14 |
Rhone Poulenc Rorer Sa |
Compositions antitumorales contenant des dérivés du taxane.
|
|
US6214388B1
(en)
*
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
|
US6210707B1
(en)
*
|
1996-11-12 |
2001-04-03 |
The Regents Of The University Of California |
Methods of forming protein-linked lipidic microparticles, and compositions thereof
|
|
KR19990029749A
(ko)
*
|
1997-09-17 |
1999-04-26 |
미우라 아끼라 |
2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
|
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US6410328B1
(en)
*
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
|
ES2224299T3
(es)
*
|
1998-02-23 |
2005-03-01 |
Cilag Ag International |
Dispersion liposomal de eritroyetina.
|
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
|
AU1678900A
(en)
*
|
1998-08-11 |
2000-03-06 |
All India Institute Of Medical Sciences |
A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
|
|
US20030049262A1
(en)
*
|
1998-10-02 |
2003-03-13 |
Susan Love |
Methods for identification, diagnosis, and treatment of breast cancer
|
|
US20030039959A1
(en)
*
|
1998-10-02 |
2003-02-27 |
Susan Love |
Methods for identification, diagnosis, and treatment of breast cancer
|
|
WO2000054807A1
(en)
*
|
1999-03-17 |
2000-09-21 |
Mitsubishi Chemical Corporation |
Ligand-bonded complex
|
|
US6333348B1
(en)
*
|
1999-04-09 |
2001-12-25 |
Aventis Pharma S.A. |
Use of docetaxel for treating cancers
|
|
SI1176981T1
(sl)
|
1999-05-07 |
2006-04-30 |
Genentech Inc |
Zdravljenje avtoimunskih bolezni z antagonisti, ki se vezejo na B celicne povrsinske markerje
|
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
BRPI0012198B8
(pt)
|
1999-06-25 |
2021-05-25 |
Genentech Inc |
anticorpos humanizados, composição e imunoconjugado
|
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
|
GB9915074D0
(en)
*
|
1999-06-28 |
1999-08-25 |
Cortecs Plc |
Ligand-binding composition
|
|
EP2110138A1
(en)
|
1999-08-27 |
2009-10-21 |
Genentech, Inc. |
Dosages for treatment of anti-erbB2 antibodies
|
|
WO2001041738A2
(en)
*
|
1999-12-10 |
2001-06-14 |
Celator Technologies Inc. |
Lipid carrier compositions with protected surface reactive functions
|
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
|
MXPA02010011A
(es)
|
2000-04-11 |
2003-04-25 |
Genentech Inc |
Anticuerpos multivalentes y usos para los mismos.
|
|
AU2001259271A1
(en)
*
|
2000-04-28 |
2001-11-12 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
|
AU2001264696B2
(en)
|
2000-05-19 |
2007-01-04 |
Genentech, Inc. |
Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
|
|
WO2001097858A2
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
|
AU2002246510B2
(en)
|
2000-11-09 |
2007-09-20 |
Neopharm, Inc. |
SN-38 lipid complexes and methods of use
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
HUP0101480A2
(hu)
*
|
2001-04-11 |
2004-01-28 |
István Horváth |
Eljárás koleszterinből nyerhető baktérium-méretű partikulák előállítására
|
|
US20050013810A1
(en)
*
|
2001-05-08 |
2005-01-20 |
Waller Edmund K |
Regulating immune response using dendritic cells
|
|
WO2003030864A1
(en)
*
|
2001-05-29 |
2003-04-17 |
Neopharm, Inc. |
Liposomal formulation of irinotecan
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
AU2002318371B2
(en)
|
2001-06-20 |
2006-06-15 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
KR101008758B1
(ko)
|
2001-09-18 |
2011-01-14 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
|
NZ533933A
(en)
|
2002-01-02 |
2008-06-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of glioma tumor
|
|
EP1487273B1
(en)
|
2002-02-13 |
2009-01-21 |
Immunology Laboratories, Inc. |
Compositions and methods for treatment of microbial infections
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
KR20040101502A
(ko)
|
2002-04-16 |
2004-12-02 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
|
KR100470535B1
(ko)
*
|
2002-06-27 |
2005-02-22 |
재단법인서울대학교산학협력재단 |
유피에이 항체 부착 이뮤노리포좀
|
|
AU2003273218C1
(en)
|
2002-07-15 |
2019-01-17 |
F. Hoffmann - La Roche Ag |
Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
|
|
ATE536188T1
(de)
|
2002-08-14 |
2011-12-15 |
Macrogenics Inc |
Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
|
|
US20060030578A1
(en)
*
|
2002-08-20 |
2006-02-09 |
Neopharm, Inc. |
Pharmaceutically active lipid based formulation of irinotecan
|
|
AU2003296897A1
(en)
*
|
2002-08-20 |
2004-05-04 |
Neopharm, Inc. |
Pharmaceutical formulations of camptothecine derivatives
|
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
MXPA05006579A
(es)
*
|
2002-12-19 |
2005-12-14 |
Johnson & Johnson |
Metodo para tratar el crecimiento de tejido angiogenico.
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
DE602004020061D1
(de)
|
2003-04-09 |
2009-04-30 |
Genentech Inc |
Behandlung von autoimmunkrankheit bei einem patienten mit unzureichendem ansprechen auf einen tnf-alpha-hemmer
|
|
EP3594228A1
(en)
|
2003-07-08 |
2020-01-15 |
Genentech, Inc. |
Il-17a/f heterologous polypedtides and therapeutic uses thereof
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
WO2005037858A2
(en)
*
|
2003-10-16 |
2005-04-28 |
University Of Massachusetts |
Template-directed assembly of receptor signaling complexes
|
|
WO2005040163A1
(en)
|
2003-10-28 |
2005-05-06 |
Dr. Reddy's Laboratories Ltd |
Heterocyclic compounds that block the effects of advanced glycation end products (age)
|
|
US20050147664A1
(en)
*
|
2003-11-13 |
2005-07-07 |
Elan Pharma International Ltd. |
Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
|
|
NZ547558A
(en)
|
2003-11-17 |
2009-06-26 |
Genentech Inc |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
EP3653641A1
(en)
|
2004-02-19 |
2020-05-20 |
Genentech, Inc. |
Cdr-repaired antibodies
|
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
|
EP4218730B1
(en)
|
2004-05-03 |
2023-11-01 |
Ipsen Biopharm Ltd. |
Liposomes useful for drug delivery
|
|
ZA200610158B
(en)
|
2004-06-04 |
2008-07-30 |
Genentech Inc |
Method for treating multiple sclerosis
|
|
CA2565961A1
(en)
|
2004-07-15 |
2006-02-23 |
Xencor, Inc. |
Optimized fc variants
|
|
JP4433918B2
(ja)
*
|
2004-07-15 |
2010-03-17 |
コニカミノルタエムジー株式会社 |
画像形成方法
|
|
KR101222254B1
(ko)
|
2004-07-26 |
2013-01-16 |
제넨테크, 인크. |
간세포 성장 인자 활성화를 조정하기 위한 조성물 및 방법
|
|
ATE401057T1
(de)
*
|
2004-10-08 |
2008-08-15 |
Alza Corp |
Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
|
WO2006052767A2
(en)
*
|
2004-11-05 |
2006-05-18 |
Inex Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal camptothecin formulations
|
|
KR100651728B1
(ko)
*
|
2004-11-10 |
2006-12-06 |
한국전자통신연구원 |
정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
|
|
CA2587617C
(en)
|
2004-11-12 |
2011-02-01 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
CN101437551A
(zh)
*
|
2004-11-19 |
2009-05-20 |
皇家飞利浦电子股份有限公司 |
用于分子成像的超声造影剂
|
|
ATE462726T1
(de)
|
2005-01-07 |
2010-04-15 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
|
CA2592177A1
(en)
|
2005-01-21 |
2006-07-27 |
Genentech, Inc. |
Fixed dosing of her antibodies
|
|
WO2006086730A2
(en)
*
|
2005-02-09 |
2006-08-17 |
Genentech, Inc. |
Inhibiting her2 shedding with matrix metalloprotease antagonists
|
|
CA2596133C
(en)
|
2005-02-23 |
2016-11-15 |
Genentech, Inc. |
Extending time to disease progression or survival in cancer patients
|
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
|
CA2597325A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
|
CA2605560A1
(en)
*
|
2005-04-22 |
2006-11-02 |
Kristen Hjortsvang |
Immunoliposome composition for targeting to a her2 cell receptor
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
CA2610709A1
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
|
WO2007005754A2
(en)
*
|
2005-07-01 |
2007-01-11 |
Alza Corporation |
Liposomal delivery vehicle for hydrophobic drugs
|
|
US7557190B2
(en)
|
2005-07-08 |
2009-07-07 |
Xencor, Inc. |
Optimized proteins that target Ep-CAM
|
|
US8591457B2
(en)
*
|
2005-08-10 |
2013-11-26 |
Alza Corporation |
Method for making a needle-free jet injection drug delivery device
|
|
EP1995321A2
(en)
|
2005-08-15 |
2008-11-26 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
ES2272178B1
(es)
*
|
2005-09-19 |
2008-03-16 |
Daniel Serrano Gil |
Una composicion para ser administrada a un mamifero o a un ser humano.
|
|
US20090155272A1
(en)
*
|
2005-09-30 |
2009-06-18 |
Muschler John L |
Targeted pharmaceuticals and ligands
|
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
US20070172520A1
(en)
*
|
2005-11-18 |
2007-07-26 |
University Of South Florida |
Immunotargeting of Nonionic Surfactant Vesicles
|
|
EP2002714A1
(en)
|
2005-11-21 |
2008-12-17 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
|
CA2633742A1
(en)
*
|
2005-12-22 |
2007-06-28 |
Domantis Limited |
Composition
|
|
EP1988768A2
(en)
|
2006-02-17 |
2008-11-12 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
KR20080110810A
(ko)
|
2006-03-23 |
2008-12-19 |
노파르티스 아게 |
항-종양 세포 항원 항체 치료제
|
|
EP2007428A2
(en)
|
2006-04-05 |
2008-12-31 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
|
JP2009536022A
(ja)
|
2006-04-19 |
2009-10-08 |
ジェネンテック・インコーポレーテッド |
新規の遺伝子破壊、それに関連する組成物および方法
|
|
US20070281034A1
(en)
*
|
2006-05-15 |
2007-12-06 |
Kirpotin Dmitri B |
Magnetic microparticles comprising organic substances
|
|
EP2522678A1
(en)
|
2006-05-15 |
2012-11-14 |
Sea Lane Biotechnologies, LLC |
Neutralizing antibodies to influenza viruses
|
|
LT2029173T
(lt)
|
2006-06-26 |
2016-11-10 |
Macrogenics, Inc. |
Fc riib specifiniai antikūnai ir jų panaudojimo būdai
|
|
US8541190B2
(en)
*
|
2006-06-28 |
2013-09-24 |
Robert M. Weis |
Methods and materials for in vitro analysis and/or use of membrane-associated proteins, portions thereof or variants thereof
|
|
ES2612383T3
(es)
|
2006-07-19 |
2017-05-16 |
The Trustees Of The University Of Pennsylvania |
WSX-1/IL-27 como una diana para respuestas antiinflamatorias
|
|
WO2008013918A2
(en)
|
2006-07-26 |
2008-01-31 |
Myelin Repair Foundation, Inc. |
Cell cycle regulation and differentiation
|
|
AU2007284651B2
(en)
|
2006-08-09 |
2014-03-20 |
Institute For Systems Biology |
Organ-specific proteins and methods of their use
|
|
AU2007285976B2
(en)
|
2006-08-14 |
2011-08-18 |
Xencor, Inc |
Optimized antibodies that target CD19
|
|
EP2423332A1
(en)
|
2006-08-25 |
2012-02-29 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
|
CN101209243B
(zh)
*
|
2006-12-29 |
2010-12-08 |
石药集团中奇制药技术（石家庄）有限公司 |
一种脂质体药物及其制备方法
|
|
CA2677108A1
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
US8367052B2
(en)
|
2007-03-26 |
2013-02-05 |
General Regeneratives Holdings Inc. |
Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
|
|
DK2176298T3
(en)
|
2007-05-30 |
2018-02-12 |
Xencor Inc |
Methods and compositions for inhibiting CD32B-expressing cells
|
|
US9551033B2
(en)
*
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
EP2592156B1
(en)
|
2007-06-08 |
2016-04-20 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
SG183044A1
(en)
|
2007-07-16 |
2012-08-30 |
Genentech Inc |
Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
|
|
JP5469600B2
(ja)
|
2007-07-16 |
2014-04-16 |
ジェネンテック， インコーポレイテッド |
抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
|
|
JPWO2009020094A1
(ja)
*
|
2007-08-09 |
2010-11-04 |
第一三共株式会社 |
疎水性分子で修飾した抗体
|
|
WO2009028639A1
(ja)
|
2007-08-30 |
2009-03-05 |
Daiichi Sankyo Company, Limited |
抗ｅｐｈａ２抗体
|
|
PT2220116E
(pt)
|
2007-11-12 |
2012-12-07 |
Theraclone Sciences Inc |
Composições e métodos para a terapia e o diagnóstico da gripe
|
|
DK2808343T3
(da)
|
2007-12-26 |
2019-08-19 |
Xencor Inc |
Fc-varianter med ændret binding til FcRn
|
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
UA106586C2
(uk)
|
2008-01-31 |
2014-09-25 |
Дженентек, Інк. |
Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
JP5544309B2
(ja)
|
2008-03-10 |
2014-07-09 |
セラクローン サイエンシーズ， インコーポレイテッド |
サイトメガロウイルス感染の治療および診断のための組成物および方法
|
|
CN102046656A
(zh)
|
2008-03-28 |
2011-05-04 |
航道生物技术有限责任公司 |
针对病毒抗原的中和性分子
|
|
ES2533480T3
(es)
|
2008-05-16 |
2015-04-10 |
F. Hoffmann-La Roche Ag |
Uso de biomarcadores para evaluar el tratamiento de trastornos inflamatorios gastrointestinales con antagonistas de la integrina beta7
|
|
ITMI20081052A1
(it)
*
|
2008-06-10 |
2009-12-11 |
Univ Milano Bicocca |
Liposomi in grado di legare efficacemente il peptide beta-amiloide
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
WO2010006282A2
(en)
|
2008-07-10 |
2010-01-14 |
Serina Therapeutics, Inc. |
Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
|
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
US20120027843A1
(en)
*
|
2009-02-04 |
2012-02-02 |
Tetsuo Minamino |
Hb-egf bound protein complex
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
NZ594665A
(en)
|
2009-03-20 |
2013-08-30 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
BRPI1012676A2
(pt)
|
2009-04-01 |
2016-04-05 |
Genentech Inc |
anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
|
|
PE20120628A1
(es)
|
2009-04-01 |
2012-05-26 |
Genentech Inc |
Antagonistas de il-17a y/o il-17f
|
|
CN102459340A
(zh)
|
2009-04-23 |
2012-05-16 |
特罗科隆科学有限公司 |
粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
|
|
AU2010249787A1
(en)
|
2009-05-20 |
2011-12-22 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
US20120121586A1
(en)
|
2009-05-29 |
2012-05-17 |
Astrid Kiermaier |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
|
KR101829073B1
(ko)
|
2009-06-26 |
2018-02-13 |
아이2 파마슈티컬스, 인크. |
대리 경쇄의 발현
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
KR20120105446A
(ko)
|
2009-10-22 |
2012-09-25 |
제넨테크, 인크. |
대식세포-자극 단백질의 헵신 활성화를 조정하기 위한 방법 및 조성물
|
|
SG10201408598XA
(en)
|
2009-11-30 |
2015-02-27 |
Genentech Inc |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
|
|
EP2509997B1
(en)
|
2009-12-07 |
2017-08-30 |
i2 Pharmaceuticals, Inc. |
Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
|
|
SI2516468T1
(sl)
|
2009-12-23 |
2016-06-30 |
Synimmune Gmbh |
Protitelesa proti flt3 in postopki uporabe istih
|
|
CN102781964B
(zh)
|
2009-12-28 |
2015-11-25 |
肿瘤疗法科学股份有限公司 |
抗cdh3抗体及其用途
|
|
WO2011091154A2
(en)
*
|
2010-01-21 |
2011-07-28 |
The Regents Of The University Of California |
Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
|
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
|
WO2011103242A1
(en)
|
2010-02-18 |
2011-08-25 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
|
TW201437228A
(zh)
|
2010-02-23 |
2014-10-01 |
Genentech Inc |
用於診斷及治療腫瘤之組合物及方法
|
|
JP2013523098A
(ja)
|
2010-03-29 |
2013-06-17 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
BR112012028010A2
(pt)
|
2010-05-03 |
2017-09-26 |
Genentech Inc |
anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
|
|
EP2566512A1
(en)
|
2010-05-04 |
2013-03-13 |
Merrimack Pharmaceuticals, Inc. |
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
US8900590B2
(en)
|
2010-08-12 |
2014-12-02 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
|
EP4226935A3
(en)
|
2010-08-31 |
2023-09-06 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
|
SG188324A1
(en)
|
2010-09-03 |
2013-04-30 |
Academia Sinica |
Anti-c-met antibody and methods of use thereof
|
|
TW201307385A
(zh)
|
2010-10-25 |
2013-02-16 |
Genentech Inc |
胃腸炎症和銀屑病以及哮喘的治療
|
|
EP2640831A1
(en)
|
2010-11-17 |
2013-09-25 |
Sea Lane Biotechnologies,llc. |
Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
|
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
|
JP6208582B2
(ja)
|
2010-12-06 |
2017-10-04 |
メリマック ファーマシューティカルズ インコーポレーティッド |
アントラサイクリン系化学療法剤を含有しているｅｒｂｂ２標的免疫リポソームによる治療における心臓毒性を抑制するための用量及び投与
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
WO2012112489A2
(en)
|
2011-02-14 |
2012-08-23 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
AU2012217685B2
(en)
|
2011-02-15 |
2017-05-18 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
BR112013023576A2
(pt)
|
2011-03-15 |
2016-12-06 |
Theraclone Sciences Inc |
composições e métodos para a terapia e diagnóstico de influenza
|
|
MY189494A
(en)
|
2011-03-31 |
2022-02-16 |
Genentech Inc |
Methods of administering beta7 integrin antagonists
|
|
KR101589135B1
(ko)
|
2011-04-20 |
2016-01-29 |
주식회사 셀앤바이오 |
인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
|
|
PT2699264T
(pt)
|
2011-04-20 |
2018-05-23 |
Medimmune Llc |
Anticorpos e outras moléculas que ligam b7-h1 e pd-1
|
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
|
US20150045540A1
(en)
|
2011-06-28 |
2015-02-12 |
Sea Lane Biotechnologies, Llc |
Multispecific stacked variable domain binding proteins
|
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
|
EP2756094B1
(en)
|
2011-08-15 |
2017-12-27 |
Medlmmune, LLC |
Anti-b7-h4 antibodies and their uses
|
|
CA2842375A1
(en)
|
2011-08-17 |
2013-02-21 |
Erica Jackson |
Neuregulin antibodies and uses thereof
|
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
|
MX2014003313A
(es)
|
2011-09-23 |
2014-07-09 |
Amgen Res Munich Gmbh |
Moleculas de union biespecificas para 5t4 y cd3.
|
|
WO2013063229A1
(en)
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
|
|
SG11201401815XA
(en)
|
2011-10-28 |
2014-05-29 |
Genentech Inc |
Therapeutic combinations and methods of treating melanoma
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
SG11201402510TA
(en)
|
2011-11-30 |
2014-06-27 |
Genentech Inc |
Erbb3 mutations in cancer
|
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
|
JP2015501839A
(ja)
|
2011-12-15 |
2015-01-19 |
ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ |
受容体に対する親和性が増大した変異型ｌｉｇｈｔ分子を使用する癌療法のための方法および組成物
|
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
|
SG11201404979RA
(en)
*
|
2012-02-17 |
2014-10-30 |
Celsion Corp |
Thermosensitive nanoparticle formulations and method of making the same
|
|
WO2013128027A1
(en)
|
2012-03-01 |
2013-09-06 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
|
DK2825156T3
(en)
|
2012-03-16 |
2017-10-30 |
Merck Patent Gmbh |
TARGETED AMINO ACID LIPIDS
|
|
CA2867184C
(en)
|
2012-03-16 |
2020-09-01 |
Merck Patent Gmbh |
Aminoacid lipids
|
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
|
JP6188681B2
(ja)
|
2012-04-09 |
2017-08-30 |
第一三共株式会社 |
抗ｆｇｆｒ２抗体
|
|
TWI606065B
(zh)
|
2012-04-27 |
2017-11-21 |
第一三共股份有限公司 |
抗ｒｏｂｏ４抗體
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
SG10201701165TA
(en)
|
2012-08-14 |
2017-03-30 |
Univ Nanyang Tech |
Angiopoietin-like 4 antibody and a method of its use in cancer treatment
|
|
CN104870056A
(zh)
|
2012-10-05 |
2015-08-26 |
弗·哈夫曼-拉罗切有限公司 |
用于诊断和治疗炎性肠病的方法
|
|
MX2015005992A
(es)
|
2012-11-20 |
2016-03-07 |
Spectrum Pharmaceuticals Inc |
Metodo mejorado para la preparacion de la vincristina liposomal encapsulada para el uso terapeutico.
|
|
EP2926142B2
(en)
|
2012-11-30 |
2022-07-06 |
F. Hoffmann-La Roche AG |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
|
AU2013355337B2
(en)
|
2012-12-03 |
2018-07-12 |
Merrimack Pharmaceuticals, Inc. |
Combination therapy for treating HER2-positive cancers
|
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
HUE045859T2
(hu)
|
2013-03-15 |
2020-01-28 |
Amgen Res Munich Gmbh |
N-terminális ABP-t tartalmazó, egyláncú kötõmolekulák
|
|
EP2970446A1
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antibody constructs for influenza m2 and cd3
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
|
WO2014145654A1
(en)
|
2013-03-15 |
2014-09-18 |
The Trustees Of The University Of Pennsylvania |
Method for the site-specific covalent cross-linking of antibodies to surfaces
|
|
CN105143876B
(zh)
|
2013-03-27 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
|
|
CN106414489A
(zh)
|
2013-05-24 |
2017-02-15 |
米迪缪尼有限公司 |
抗-b7-h5抗体及其用途
|
|
EP3381939A1
(en)
|
2013-05-31 |
2018-10-03 |
Genentech, Inc. |
Anti-wall teichoic antibodies and conjugates
|
|
BR112015029754A2
(pt)
|
2013-05-31 |
2017-09-26 |
Genentech Inc |
anticorpos anti-teicoico da parede e conjugados
|
|
KR20180021234A
(ko)
|
2013-08-12 |
2018-02-28 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
|
TWI688401B
(zh)
|
2013-09-13 |
2020-03-21 |
美商安進公司 |
用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
|
|
JP6509735B2
(ja)
|
2013-10-08 |
2019-05-08 |
第一三共株式会社 |
抗ｆｇｆｒ２抗体と他剤の組合せ
|
|
WO2015148809A1
(en)
|
2014-03-27 |
2015-10-01 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
JP6749312B2
(ja)
|
2014-07-31 |
2020-09-02 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ |
最適化された種間特異的二重特異性単鎖抗体コンストラクト
|
|
US20160045596A1
(en)
|
2014-08-05 |
2016-02-18 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
|
|
WO2016090040A1
(en)
|
2014-12-03 |
2016-06-09 |
Genentech, Inc. |
Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
|
|
BR112017011325A2
(pt)
|
2014-12-03 |
2020-07-21 |
Genentech, Inc. |
?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
|
|
WO2016123329A2
(en)
|
2015-01-28 |
2016-08-04 |
Genentech, Inc. |
Gene expression markers and treatment of multiple sclerosis
|
|
DK3259597T3
(da)
|
2015-02-19 |
2022-05-09 |
Compugen Ltd |
Pvrig-polypeptider og fremgangsmåder til behandling
|
|
PT3258951T
(pt)
|
2015-02-19 |
2020-08-18 |
Compugen Ltd |
Anticorpos anti-pvrig e métodos de utilização
|
|
EP3978530A1
(en)
|
2015-02-26 |
2022-04-06 |
F. Hoffmann-La Roche AG |
Integrin beta7 antagonists and methods of treating crohn's disease
|
|
SI3283524T1
(sl)
|
2015-04-17 |
2023-06-30 |
Amgen Research (Munich) Gmbh |
Bispecifični konstrukti protiteles za CDH3 in CD3
|
|
US11123440B2
(en)
|
2015-05-12 |
2021-09-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for making antibody conjugates
|
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
HK1255200A1
(zh)
|
2015-05-29 |
2019-08-09 |
F. Hoffmann-La Roche Ag |
癌症中pd-l1启动子甲基化
|
|
DK3322733T3
(da)
|
2015-07-13 |
2021-10-18 |
Compugen Ltd |
Hide1-sammensætninger og fremgangsmåder
|
|
TWI678213B
(zh)
|
2015-07-22 |
2019-12-01 |
美商史倍壯製藥公司 |
用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
Dll3及cd3抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
SG10201913073YA
(en)
|
2015-08-20 |
2020-03-30 |
Ipsen Biopharm Ltd |
Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
|
|
US20170049775A1
(en)
|
2015-08-21 |
2017-02-23 |
Merrimack Pharmaceuticals, Inc. |
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
|
|
PT3359572T
(pt)
|
2015-10-06 |
2025-01-27 |
H Hoffnabb La Roche Ag |
Método para o tratamento da esclerose múltipla
|
|
CN114099437A
(zh)
|
2015-10-16 |
2022-03-01 |
易普森生物制药有限公司 |
稳定喜树碱药物组合物
|
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
|
US11253590B2
(en)
|
2015-12-02 |
2022-02-22 |
Stsciences, Inc. |
Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
|
|
US10875920B2
(en)
|
2015-12-02 |
2020-12-29 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究（慕尼黑）公司 |
包含雙特異性抗體建構物之醫藥組合物
|
|
UY37105A
(es)
|
2016-02-03 |
2017-09-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
|
|
SG11201805770UA
(en)
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
|
ES2963807T3
(es)
|
2016-06-08 |
2024-04-02 |
Xencor Inc |
Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B
|
|
EP3487521A4
(en)
|
2016-07-21 |
2020-07-01 |
Emory University |
ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM
|
|
EP3512564B1
(en)
|
2016-09-14 |
2024-01-17 |
The Trustees of The University of Pennsylvania |
Proximity-based sortase-mediated protein purification and ligation
|
|
JPWO2018070390A1
(ja)
|
2016-10-12 |
2019-08-22 |
第一三共株式会社 |
抗ｒｏｂｏ４抗体と他剤を含む組成物
|
|
RU2761953C2
(ru)
|
2016-11-02 |
2021-12-14 |
Ипсен Биофарм Лтд. |
Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
|
|
BR112019012901A2
(pt)
|
2016-12-22 |
2020-01-07 |
Daiichi Sankyo Company, Limited |
Anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo e uma molécula que se ligue ao cd3 humano e ao cd3 de macaco cinomolgo, composição farmacêutica, e, molécula
|
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
|
WO2018147245A1
(ja)
|
2017-02-07 |
2018-08-16 |
第一三共株式会社 |
抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子
|
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
|
TWI782000B
(zh)
|
2017-03-30 |
2022-11-01 |
日商第一三共股份有限公司 |
抗ｇｐｒ２０抗體、其製造方法及其應用
|
|
EP4230649A3
(en)
|
2017-04-25 |
2023-10-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
|
UY37726A
(es)
|
2017-05-05 |
2018-11-30 |
Amgen Inc |
Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
|
|
WO2018215535A1
(en)
|
2017-05-23 |
2018-11-29 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel cd73 antibody, preparation and uses thereof
|
|
EP3630834A1
(en)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
|
AU2018277838C1
(en)
|
2017-05-31 |
2025-08-07 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
|
JP2020522562A
(ja)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー．， インコーポレイテッド |
Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
|
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
|
KR102818021B1
(ko)
|
2017-10-05 |
2025-06-10 |
다이이찌 산쿄 가부시키가이샤 |
세포 상해성 t 세포 고갈용 조성물
|
|
KR20250111232A
(ko)
|
2017-12-11 |
2025-07-22 |
암젠 인크 |
이중특이적 항체 생성물의 연속 제조 공정
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
|
|
US20210115156A1
(en)
|
2018-04-13 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fc-engineered anti-human ige antibodies and methods of use
|
|
WO2019213416A1
(en)
|
2018-05-02 |
2019-11-07 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
|
AU2019269588A1
(en)
*
|
2018-05-15 |
2020-12-10 |
Flagship Pioneering Innovations Vi, Llc |
Pathogen control compositions and uses thereof
|
|
WO2020077212A1
(en)
|
2018-10-11 |
2020-04-16 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
|
JP7326445B2
(ja)
|
2018-12-11 |
2023-08-15 |
ディスラプション・ラブズ・インコーポレイテッド |
治療剤の送達のための組成物並びにその使用及び製造方法
|
|
JP2022537650A
(ja)
|
2019-06-13 |
2022-08-29 |
アムジエン・インコーポレーテツド |
生物製剤の製造における自動化された生物量に基づく灌流制御
|
|
US20220411511A1
(en)
|
2019-09-26 |
2022-12-29 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
|
JP2022552282A
(ja)
|
2019-10-09 |
2022-12-15 |
エスティーキューブ アンド カンパニー |
グリコシル化ｌａｇ３に対して特異的な抗体およびその使用方法
|
|
AU2020381536A1
(en)
|
2019-11-13 |
2022-04-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
|
JP7750852B2
(ja)
|
2020-03-19 |
2025-10-07 |
アムジエン・インコーポレーテツド |
ムチン１７に対する抗体及びその使用
|
|
IL301865A
(en)
|
2020-10-06 |
2023-06-01 |
Xencor Inc |
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
|
|
IL302599A
(en)
|
2020-11-06 |
2023-07-01 |
Amgen Inc |
Bispecific molecules bind multi-target antigens of increased selectivity
|
|
MX2023011127A
(es)
|
2021-03-29 |
2023-10-04 |
Daiichi Sankyo Co Ltd |
Molecula multiespecifica estable y uso de la misma.
|
|
CA3217180A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
WO2022245877A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
US20220372114A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
CN118302157A
(zh)
*
|
2021-09-30 |
2024-07-05 |
日油株式会社 |
具有细胞靶向性的脂质纳米颗粒
|
|
IL316597A
(en)
|
2022-05-12 |
2024-12-01 |
Amgen Res Munich Gmbh |
Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
|
|
AU2023330110A1
(en)
|
2022-08-22 |
2025-03-06 |
Abdera Therapeutics Inc. |
Dll3 binding molecules and uses thereof
|
|
JP2025533434A
(ja)
|
2022-09-14 |
2025-10-07 |
アムジエン・インコーポレーテツド |
二重特異性分子安定化組成物
|
|
WO2024259378A1
(en)
|
2023-06-14 |
2024-12-19 |
Amgen Inc. |
T cell engager masking molecules
|